Provider review
DudeMeds review: it explains why compounded drugs are risky, then calls its compounded GLP-1 a generic
DudeMeds has the best explanation of compounding risk we have read on a seller's own site. It sits on the testosterone page. It is accurate, and it is the reason the company gives for using commercial testosterone instead. Then move to the weight-loss side, where the same company sells semaglutide at a fraction of the brand price and describes it as an "Ozempic/Wegovy generic" and an "FDA-approved medication". There is no generic semaglutide in the United States. The word compounded appears on one page of this site, and it is not either of the GLP-1 ones.
Explains compounding risk better than any seller here, on the one product line where it doesn't apply. Then calls its compounded GLP-1 a generic.
Worth trusting if
- You want testosterone and want the commercial product rather than a compounded one
- You want to see the price before answering health questions, because here you do
- You want the brand drug and would rather see it priced openly beside the alternatives
Be skeptical if
- You need to know whether your medication is compounded, because the weight-loss pages never say
- You read "generic" as meaning an approved equivalent, because no such thing exists for these molecules
- You want to look a price up later, because none of them are text
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.dudemeds.com. A link is not a recommendation to take anything.
Provenance
What DudeMeds actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $295 a month to pay monthly; the advertised $175 needs a six-month commitment.
- Compounded tirzepatide injection — $433 a month to pay monthly; $249 on a three-month prepay.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to DudeMeds.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from DudeMeds’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“Semaglutide (Ozempic/Wegovy generic): What to expect. Semaglutide is an FDA-approved medication shown to significantly aid weight loss by reducing appetite and promoting a feeling of fullness. Semaglutide has been shown to reduce body weight by 10-15% over a 68-week period in individuals with obesity, according to clinical trials.”
Read on the DudeMeds site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults titrated to semaglutide 2.4 mg weekly, reporting a mean reduction of about 15% against about 2% on placebo. DudeMeds gives the right trial and the right duration, and states a range rather than a single figure.
The weight-loss arithmetic is fine — 10 to 15% over 68 weeks is a fair reading of STEP 1, and quoting a range rather than the best number is more honest than most of this market manages. What fails is the description of the product. There is no generic semaglutide in the United States: the molecule is on patent and no approved generic exists, so a compounded preparation cannot be one. Calling it FDA-approved compounds that, because the approval belongs to Ozempic and Wegovy, which DudeMeds sells separately on the same site for roughly nine times the price. A reader could finish this page believing they are buying an approved drug at a discount, and they are not.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim reaches past the trials
“Tirzepatide (Zepbound/Mounjaro generic): The science. Tirzepatide is an FDA-approved medication, effectively supports weight loss by mimicking hormones that regulate appetite and blood sugar levels. Tirzepatide has been shown to reduce body weight by up to 22.5% in clinical trials, offering groundbreaking results in obesity treatment.”
Read on the DudeMeds site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. It reported about 20.9% at the top dose on one analysis and 22.5% on a second — so the figure DudeMeds quotes is real, and it is the more favorable of the two.
The 22.5% survives checking, which is worth saying because it looks at first like an inflated number. SURMOUNT-1 reported two analyses at the top dose and 22.5% is the second of them — the page picks the better one and does not say so, which is a small thing rather than a false one. The problem is the same as on the semaglutide page and it is not small. Tirzepatide has no generic in the United States, so nothing sold here can be one, and the FDA approval named belongs to Zepbound and Mounjaro. Those two are also sold on this site, priced separately, at several times what this product costs.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named for either side of the business. The homepage describes DudeMeds as an online doctors office plus pharmacy and says medication ships within about 48 hours of approval, without identifying a facility, an address or a license number. The TRT pages go furthest, committing to commercial testosterone cypionate rather than a compounded preparation and explaining why — which tells you what kind of product arrives without telling you who dispensed it. The weight-loss pages make no equivalent statement in either direction: they never say the medication is compounded, and they never say it is not. Checked across eight pages on September 13, 2026.
Read on the DudeMeds site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published for any product. On testosterone DudeMeds offers something in place of test data that is arguably better: it commits to a commercially manufactured product and explains what that buys you over a compounded one, including a longer beyond-use date. Nothing comparable appears on the weight-loss side, where the product type is never stated. Its LegitScript seal links to the checker keyed to this domain and the checker resolves, which proves a certificate was issued rather than anything about what ships. One quieter point: every weight-loss price is drawn inside an image, so nothing about the commercial terms can be searched or archived either.
Read on the DudeMeds site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
DudeMeds says no face-to-face visit is required "in most states", which is its own hedge and the closest thing to a coverage statement on the site. It publishes no state list and no exclusions on the weight-loss pages, the catalog or the legal section. The TRT route does require a video visit with a doctor licensed in your state, so availability there depends on where you live. Checked September 13, 2026.
Read the full licensing claim
The operating company is named — DudeMeds LLC, in the privacy policy — which is more than most sellers here manage. No registered address, state of incorporation, medical director or individual prescriber is published.
Read on the DudeMeds site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with DudeMeds
We went through DudeMeds’s signup ourselves in September 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- What type of patient are you? — new patient or refill
- Injection or oral
- Select the medication: semaglutide, tirzepatide, or a brand name
- "What's your Commitment Level?" — the plan cards, with the prices
- For refills, a dose is chosen first: low, medium or high
- Prices come early, before any health question, which is the opposite of most sellers here.
- Every price is an image. No screen shows a dollar figure as text.
- The word compounded appears on no screen of the weight-loss signup.
- Brand pens are offered on the same screens at roughly nine times the price of the cheap products.
- The cheapest new-patient plan is $175 a month; the site's own headline says prices from $149.
- On the tirzepatide refill screen, the medium-dose card shows a vial labeled Se rather than Tz.
- The refill brand page still reads "NEW PATIENT MONTHS 1 + 2 + 3".
DudeMeds support
- care@dudemeds.com
Assessment
What holds up, and what does not
- Its testosterone pages explain why commercial product beats compounded, accurately and in detail.
- It commits to commercial testosterone cypionate rather than a compounded preparation, and says so plainly.
- The semaglutide figure — 10 to 15% over 68 weeks — matches STEP 1 and is given as a range.
Show 5 more
- The tirzepatide figure of 22.5% is a real number from SURMOUNT-1, not an invented one.
- Brand-name Ozempic, Wegovy, Mounjaro and Zepbound are sold and priced openly alongside the cheaper options.
- Prices appear before any health question rather than after a home address.
- The operating company is named in the privacy policy, which most sellers here avoid.
- Its LegitScript certification is real and keyed to this domain.
- It calls its semaglutide an "Ozempic/Wegovy generic" and no generic semaglutide exists in the United States.
- It calls its tirzepatide a "Zepbound/Mounjaro generic", and the same is true of that molecule.
- Both weight-loss pages describe the medication as FDA-approved, which the compounded product is not.
Show 5 more
- The word compounded appears on one page of the site, and it is the testosterone one.
- The medication pages borrow the section headings of an approved drug's label for a product with none.
- No pharmacy is named for either the weight-loss or the testosterone side.
- No clinician, medical director or prescriber is named anywhere.
- Every weight-loss price is drawn inside an image and cannot be searched or archived.
Verdict
The bottom line
Read the testosterone FAQ, then read the semaglutide page, and notice that the same company wrote both. The first explains exactly why a compounded drug is a different proposition from an approved one; the second sells a compounded drug using the words generic and FDA-approved. Nothing here misrepresents what the molecules do. The trial figures check out. What is misrepresented is what you would be buying. Ask DudeMeds directly whether the medication is compounded and which pharmacy makes it, and get the answer in writing before you pay.
Opens www.dudemeds.com. A link is not a recommendation to take anything.
Two pages, one company
From `/testosterone-trt`, answering its own question "Why does DudeMeds only use Commercial injectable Testosterone and not compounded?":
"Commercial testosterone is FDA-approved, produced in sterile environments, and rigorously tested… In contrast, compounded testosterone lacks FDA oversight, leading to variability in potency, quality, and sterility. It also carries a higher risk of contamination…"
That is correct, and it is better than almost anything else written on the subject by a seller.
From `/medication-page/semaglutide`, on the same site:
"Semaglutide (Ozempic/Wegovy generic): What to expect"
And from `/weight-loss`:
"Semaglutide is an FDA-approved medication shown to significantly aid weight loss…"
Full analysis — 5 more sectionsThere is no generic semaglutide · How we know which one is being sold · The trial numbers are fine · A label that isn't one · What to ask
There is no generic semaglutide
Not in the United States. Semaglutide and tirzepatide are both on patent, and no approved generic exists for either molecule.
A generic is an FDA-approved copy demonstrated to be bioequivalent to the original. A compounded preparation is made to order by a pharmacy, is not FDA-approved, and has not been evaluated by the FDA for safety, effectiveness or quality.
They are close to opposites. The testosterone page says so.
How we know which one is being sold
Not by inference. By DudeMeds' own pricing, on the pages you click through to buy:
| Product | Price | |---|---| | Ozempic, Wegovy | $1,585/mo | | Mounjaro, Zepbound | $1,350/mo | | "Semaglutide" | $175–$295/mo | | "Tirzepatide" | $249–$433/mo |
A seller offering Wegovy at $1,585 and semaglutide at $175 is not offering the same product twice.
We also checked the word itself. Across eight pages captured on 13 September 2026 — both medication pages, the weight-loss landing page, the medication index and every plan screen — "compound" appears once, on the testosterone page.
The trial numbers are fine
This is worth stating clearly, because the failure here is narrow and it would be unfair to widen it.
Semaglutide: "10-15% over a 68-week period". STEP 1 randomized 1,961 adults and reported about 15% at 68 weeks. 1 Right trial, right duration, and a range rather than the single best figure.
Tirzepatide: "up to 22.5%". SURMOUNT-1 reported roughly 20.9% at the top dose on one analysis and 22.5% on another. 2 The page uses the more favorable one without saying which — a small thing, and not a fabricated number.
So DudeMeds is not exaggerating what these drugs do. It is misdescribing what it sells.
A label that isn't one
Both medication pages are laid out under the headings of an FDA package insert — Prescribing Information, Indications and Usage, Clinical Pharmacology, Contraindications, Warnings and Precautions.
The text under them is short and broadly accurate. But that structure belongs to a drug with an approved label, and a compounded preparation does not have one.
What to ask
Two questions, and get them answered in writing:
1. Is the medication compounded? The pages never say. The price says yes. 2. Which pharmacy makes it? No facility is named for either product line.
The company that wrote the testosterone FAQ knows why both questions matter.
Questions
Frequently asked questions
Is DudeMeds selling real Ozempic?
Both are on offer and the prices separate them. Ozempic and Wegovy are listed at $1,585 a month and Mounjaro and Zepbound at $1,350, as their own products. The cheaper semaglutide and tirzepatide, from $175 and $249, are a different thing — compounded, though the pages selling them never use the word.
Is there such a thing as generic semaglutide?
Not in the United States. Semaglutide and tirzepatide are both on patent and neither has an approved generic. A generic is an FDA-approved copy proven bioequivalent to the original; a compounded preparation is made to order by a pharmacy and has not been evaluated by the FDA at all.
Are the weight-loss figures accurate?
Yes. The semaglutide claim of 10 to 15% over 68 weeks matches STEP 1, and quoting a range is more honest than picking the best number. The tirzepatide claim of up to 22.5% is a real SURMOUNT-1 result, though it is the more favorable of two analyses and the page doesn't say so.
What does DudeMeds say about compounded drugs?
On testosterone, a great deal, and it is accurate — compounded product lacks FDA oversight, varies in potency and sterility, and carries a higher contamination risk. That is the reason it gives for using commercial testosterone instead. The GLP-1 pages make no equivalent statement in either direction.
Why can't I find the weight-loss prices by searching?
Because none of them are text. Every plan card is a picture with the price drawn into the artwork, so a search engine, a screen reader and a price tracker see an image and nothing more. It is also why the figures in this review had to be read off screenshots one screen at a time.
Glossary
Key terms
Show definitions
- Generic
- An FDA-approved copy of an approved drug, demonstrated to be bioequivalent to it. No generic semaglutide or tirzepatide exists in the United States — both molecules remain on patent.
- 503A
- A pharmacy that makes a drug to order for one named patient with a prescription. What it produces is not FDA-approved, and the FDA has not evaluated its safety, effectiveness or quality.
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021, reporting a mean reduction of about 15%.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022, reporting about 20.9% at the top dose on its primary analysis and 22.5% on a second.
Compare
Others selling what DudeMeds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off DudeMeds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, about 20.9% mean reduction at the top dose on the treatment-regimen analysis and 22.5% on the efficacy analysis, at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.